| Wissenschaftl. Titel | A first-in-human, open-label Phase 1/2 study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with relapsed/refractory advanced solid tumors |
| Erkrankung | |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 19.12.2024 Admin07
geändert 19.12.2024 Admin07